Zydus Lifesciences Ltd
Zydus Lifesciences Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #56 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Zydus Lifesciences Ltd Q2 FY27 key numbers
- Revenue
- Total Income from Operations (Q2 FY27): Rs. 79,096 mn, up 29.2% YoY.
As stated in Zydus Lifesciences Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on Zydus Lifesciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Total Income from Operations (Q2 FY27): Rs. 79,096 mn, up 29.2% YoY (Page 14). EBITDA for Q2 FY27: Rs. 18,945 mn.
From Zydus Lifesciences Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Zydus Lifesciences' revenue grow in the September 2026 quarter?
- Total Income from Operations (Q2 FY27): Rs. 79,096 mn, up 29.2% YoY (Page 14)
- India Formulations Sales (Q2 FY27): Rs. 18,844 mn, up 18.3% YoY (Page 7)
- North America Formulations Sales (Q2 FY27): Rs. 33,145 mn, up 20.8% YoY (Page 8)
- International Markets Formulations Sales (Q2 FY27): Rs. 10,009 mn, up 33.2% YoY (Page 9)
2 more points from Zydus Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
What happened to Zydus Lifesciences' margins in Q2 FY27?
See what Zydus Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
What capex is Zydus Lifesciences planning?
- Organic capex for Q2 FY27 was Rs. 4,655 million (Page 6).
- USFDA inspections at SEZ II, Ahmedabad and Moraiya formulations facilities concluded with observations; post-inspection approval for a transdermal product at Moraiya site on October 21, 2026 (Page 4).
- The company continues investment to build resilient product portfolio in North America, with ongoing ANDA filings and approvals: 4 filings and 12 approvals in H1 FY27 including 2 tentative approvals (Page 8).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Zydus Lifesciences raising money or cutting debt?
See what Zydus Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Zydus Lifesciences' order book?
Zydus Lifesciences Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹7.6K Cr, net profit ₹1.3K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zydus Lifesciences's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Lupin (Q2 FY27)
Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13) . Key investor presentation takeaways from Lupin Ltd's Q2 FY27 investor presentation — and how it ran
- Glaxosmithkline Pharmaceuticals (Q2 FY27)
97,994 lakhs in the corresponding quarter of 2025, reflecting a year-on-year increase of approximately 20.8%. Key results statement takeaways from Glaxosmithkli
- Remus Pharmaceuticals (Q2 FY27)
Year-on-Year (YoY) growth: 53.4% (up from INR 4,002 Mn in H1-FY26) . Key investor presentation takeaways from Remus Pharmaceuticals Ltd's Q2 FY27 investor prese
- Amrutanjan Healt (Q2 FY27)
Q2 FY27 Net Sales:** ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q2 FY27 i
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zydus Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zydus Lifesciences Ltd Q2 FY27 results?
Total Income from Operations (Q2 FY27): Rs. 79,096 mn, up 29.2% YoY (Page 14). EBITDA for Q2 FY27: Rs. 18,945 mn.
What is Zydus Lifesciences Ltd share price analysis?
Zydus Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 25.4 with a market cap of ₹123,750 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zydus Lifesciences Ltd planning capital expenditure?
Organic capex for Q2 FY27 was Rs. 4,655 million (Page 6).
Keep Zydus Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.